Dexamethasone blocks antioestrogen- and oxidant-induced death of pituitary tumour cells.
The oestrogen receptor is fundamental to the growth and survival of the rat pituitary tumour cell line, GH(3). Our previous studies have shown that antioestrogens such as RU 58668 and ZM 182780 will reduce the rate of cell division and also induce cell death. Death of these cells in response to antioestrogen treatment appears to be due to a heightened sensitivity to reactive oxygen species (ROS). As part of a study to determine the cross-talk between steroid receptor systems in these cells, we have observed that the glucocorticoid, dexamethasone (Dex), inhibits antioestrogen-induced cell death. Cell death induced by H(2)O(2) is enhanced by ZM 182780 and this effect is also blocked by Dex. As apoptotic cell death in a number of systems involves an early loss of mitochondrial membrane potential (DeltaPsi(m)), we have performed detailed studies on the time-course of DeltaPsi(m) loss in relation to the loss in cell membrane function. These studies have indicated that a loss of DeltaPsi(m) parallels a loss of cell membrane function - this is more characteristic of necrosis than of apoptosis. From microscopic observations of these cells in response to H(2)O(2), it has been noted that early cell membrane blebbing, induced by H(2)O(2), is blocked in the presence of ZM 182780. Cell membrane blebbing can precede necrosis as well as apoptosis and it is thought to involve cytoskeletal changes, for which localised glycolytic reactions provide ATP. These observations, together with those showing that removal of glucose, but not inhibition of mitochondrial function, enhances ROS-induced cell death, prompted studies on the glycolytic pathway. As a strong candidate mechanism, it would appear that, via an effect on one of the rate-limiting glycolytic enzymes, glyceraldehyde-3-phosphate dehydrogenase, Dex is able to overcome the antioestrogen-enhanced loss of glycolytic function following exposure of cells to ROS. This report contributes to the growing body of evidence showing that glucocorticoids provide a survival advantage to both normal and tumour cell types.
Newton
C J
CJ
Molecular Pharmacology, School of Medicine, Faculty of Health, University of Hull, Hull HU6 7RX, UK. C.J.Newton@medschool.hull.ac.uk
Bilko
D
D
Pappa
S
S
Atkin
S L
SL
D000255:Adenosine Triphosphate / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D003907:Dexamethasone / Q000494:pharmacology*; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D020847:Estrogen Receptor Modulators / Q000494:pharmacology; D004970:Estrone / Q000494:pharmacology; D005434:Flow Cytometry; D005485:Flutamide / Q000031:analogs & derivatives / Q000494:pharmacology; D000077267:Fulvestrant; D005938:Glucocorticoids / Q000494:pharmacology*; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism; D006067:Gonanes / Q000494:pharmacology; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology; D008856:Microscopy, Fluorescence; D015735:Mifepristone / Q000494:pharmacology; D010911:Pituitary Neoplasms; D017382:Reactive Oxygen Species / Q000378:metabolism; D020239:Receptor Cross-Talk; D011956:Receptors, Cell Surface / Q000187:drug effects*; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000378:metabolism; D005466:Fluorocarbons
D000255:Adenosine Triphosphate; D003907:Dexamethasone; D004958:Estradiol; D020847:Estrogen Receptor Modulators; D004970:Estrone; D005485:Flutamide; D000077267:Fulvestrant; D005938:Glucocorticoids; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D006067:Gonanes; D006861:Hydrogen Peroxide; D015735:Mifepristone; D017382:Reactive Oxygen Species; D011956:Receptors, Cell Surface; C086511:RU 58668; D005466:Fluorocarbons; C014290:hydroxyflutamide; C053238:onapristone